News | January 06, 2012

Plans Made for Market Reintroduction of CardioGen-82

January 6, 2012 – Bracco Diagnostics said it plans to close out the recall process for its CardioGen-82 cardiac perfusion radiotracer with a list of actions to bring the product back to market.

The company instituted the product recall on July 29, 2011 after two cardiac patients who underwent positron emission tomography (PET) scans set off radiation detectors on the U.S. border. The increased level of radiation was due to a strontium (Sr) breakthrough from the radiotracer generator.

In a letter to customers released December 29, Bracco said during the past five months it performed the following actions:

CardioGen-82 Generator Voluntary Recall Process: All recalled generators were sent back to the manufacturer for functional and breakthrough testing. The generator testing demonstrated that each and every generator had Sr-82 and Sr-85 levels well within specification limits set forth in the prescribing information.

Clinical Assessment Program: Bracco continues to gather data in a clinical study (designated CGEN-105) at all participating institutions that have administered CardioGen-82 to patients from January 2011 through July 2011. To date, there have been no patients identified at these sites with higher than expected radiation levels.

Rb82 Generator Quality Review Program: Bracco initiated an on-site review of each facility’s daily quality control records, using the quality review process. This review was an opportunity to reinforce customer training and education and will be the basis for enhanced CardioGen-82 training quality control assessment and monitoring upon reintroduction of CardioGen-82 to the market.

Manufacturing Process Review: At the U.S. Food and Drug Administration’s (FDA) request, Bracco initiated the re-qualifying of all CardioGen components and revalidating of the manufacturing process.

Enhanced Labeling and User Training: Bracco continues to work with the FDA on enhancing the CardioGen-82 prescribing information and user training parameters to ensure proper field use. We will initiate a new quality control data repository and monitoring program upon the reintroduction of Cardiogen-82 to the market.

The company said it proposed to FDA a controlled and phased reintroduction of CardioGen-82 generators to user facilities, with data collection and evaluation of the actual field use of each generator beginning in the first quarter of 2012. Bracco said the FDA expressed support for this plan. The first step in this effort will be to implement customer requirements in advance of commercial generator availability. Bracco’s field nuclear medicine team will begin to contact each facility toward the end of January, discussing compliance training and site preparation expectations. Specific customer generator delivery schedules are not available at this time. However, customers can anticipate receiving additional information regarding generator availability by Feb. 1, 2012.

For more information: www.cardiogen.com

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....